Treatment  ||| S:0 E:10 ||| NN
of  ||| S:10 E:13 ||| IN
brain  ||| S:13 E:19 ||| NN
metastases  ||| S:19 E:30 ||| NN
in  ||| S:30 E:33 ||| IN
patients  ||| S:33 E:42 ||| NNS
with  ||| S:42 E:47 ||| IN
HER2+  ||| S:47 E:53 ||| CD
breast  ||| S:53 E:60 ||| NN
cancer  ||| S:60 E:67 ||| NN
Brain  ||| S:67 E:73 ||| NNP
metastases  ||| S:73 E:84 ||| NNS
are  ||| S:84 E:88 ||| VBP
a  ||| S:88 E:90 ||| DT
frequent  ||| S:90 E:99 ||| JJ
complication  ||| S:99 E:112 ||| NN
of  ||| S:112 E:115 ||| IN
cancer ||| S:115 E:121 ||| NN
.  ||| S:121 E:123 ||| .
However ||| S:123 E:130 ||| RB
,  ||| S:130 E:132 ||| ,
effective  ||| S:132 E:142 ||| JJ
treatments  ||| S:142 E:153 ||| NNS
are  ||| S:153 E:157 ||| VBP
available ||| S:157 E:166 ||| JJ
.  ||| S:166 E:168 ||| .
This  ||| S:168 E:173 ||| DT
article  ||| S:173 E:181 ||| NN
aims  ||| S:181 E:186 ||| VBZ
to  ||| S:186 E:189 ||| TO
review  ||| S:189 E:196 ||| VB
clinical  ||| S:196 E:205 ||| JJ
aspects  ||| S:205 E:213 ||| NNS
of  ||| S:213 E:216 ||| IN
patients  ||| S:216 E:225 ||| NNS
with  ||| S:225 E:230 ||| IN
brain  ||| S:230 E:236 ||| NN
metastases  ||| S:236 E:247 ||| VBZ
discussing  ||| S:247 E:258 ||| VBG
the  ||| S:258 E:262 ||| DT
various  ||| S:262 E:270 ||| JJ
treatment  ||| S:270 E:280 ||| NN
options  ||| S:280 E:288 ||| NNS
for  ||| S:288 E:292 ||| IN
such  ||| S:292 E:297 ||| JJ
patients ||| S:297 E:305 ||| NNS
.  ||| S:305 E:307 ||| .
It  ||| S:307 E:310 ||| PRP
will  ||| S:310 E:315 ||| MD
address  ||| S:315 E:323 ||| VB
the  ||| S:323 E:327 ||| DT
importance  ||| S:327 E:338 ||| NN
and  ||| S:338 E:342 ||| CC
significance  ||| S:342 E:355 ||| NN
of  ||| S:355 E:358 ||| IN
brain  ||| S:358 E:364 ||| NN
metastases  ||| S:364 E:375 ||| NN
in  ||| S:375 E:378 ||| IN
patients  ||| S:378 E:387 ||| NNS
with  ||| S:387 E:392 ||| IN
breast  ||| S:392 E:399 ||| JJ
cancer  ||| S:399 E:406 ||| NN
and ||| S:406 E:409 ||| CC
,  ||| S:409 E:411 ||| ,
finally ||| S:411 E:418 ||| RB
,  ||| S:418 E:420 ||| ,
review  ||| S:420 E:427 ||| VB
the  ||| S:427 E:431 ||| DT
problem  ||| S:431 E:439 ||| NN
of  ||| S:439 E:442 ||| IN
brain  ||| S:442 E:448 ||| NN
metastasis  ||| S:448 E:459 ||| VBZ
associated  ||| S:459 E:470 ||| VBN
with  ||| S:470 E:475 ||| IN
human  ||| S:475 E:481 ||| JJ
epidermal  ||| S:481 E:491 ||| JJ
growth  ||| S:491 E:498 ||| NN
factor  ||| S:498 E:505 ||| NN
receptor  ||| S:505 E:514 ||| NN
2-positive  ||| S:514 E:525 ||| NNP
( ||| S:525 E:526 ||| -LRB-
HER2+ ||| S:526 E:531 ||| NNP
)  ||| S:531 E:533 ||| -RRB-
breast  ||| S:533 E:540 ||| NN
cancer ||| S:540 E:546 ||| NN
.  ||| S:546 E:548 ||| .
With  ||| S:548 E:553 ||| IN
ever-improving  ||| S:553 E:568 ||| JJ
survival  ||| S:568 E:577 ||| NN
rates  ||| S:577 E:583 ||| NNS
of  ||| S:583 E:586 ||| IN
patients  ||| S:586 E:595 ||| NNS
with  ||| S:595 E:600 ||| IN
cancer ||| S:600 E:606 ||| NN
,  ||| S:606 E:608 ||| ,
there  ||| S:608 E:614 ||| EX
is  ||| S:614 E:617 ||| VBZ
a  ||| S:617 E:619 ||| DT
greater  ||| S:619 E:627 ||| JJR
likelihood  ||| S:627 E:638 ||| NN
that  ||| S:638 E:643 ||| IN
many  ||| S:643 E:648 ||| JJ
will  ||| S:648 E:653 ||| MD
develop  ||| S:653 E:661 ||| VB
brain  ||| S:661 E:667 ||| NN
metastases ||| S:667 E:677 ||| NN
.  ||| S:677 E:679 ||| .
Treatments  ||| S:679 E:690 ||| NNS
such  ||| S:690 E:695 ||| JJ
as  ||| S:695 E:698 ||| IN
whole  ||| S:698 E:704 ||| JJ
brain  ||| S:704 E:710 ||| NN
or  ||| S:710 E:713 ||| CC
stereotactic  ||| S:713 E:726 ||| JJ
radiotherapy  ||| S:726 E:739 ||| NN
and  ||| S:739 E:743 ||| CC
surgery  ||| S:743 E:751 ||| NN
have  ||| S:751 E:756 ||| VBP
been  ||| S:756 E:761 ||| VBN
shown  ||| S:761 E:767 ||| VBN
to  ||| S:767 E:770 ||| TO
be  ||| S:770 E:773 ||| VB
effective  ||| S:773 E:783 ||| JJ
against  ||| S:783 E:791 ||| IN
brain  ||| S:791 E:797 ||| NN
metastases ||| S:797 E:807 ||| NN
.  ||| S:807 E:809 ||| .
In  ||| S:809 E:812 ||| IN
HER2+  ||| S:812 E:818 ||| CD
breast  ||| S:818 E:825 ||| NN
cancer ||| S:825 E:831 ||| NN
,  ||| S:831 E:833 ||| ,
trastuzumab  ||| S:833 E:845 ||| NN
has  ||| S:845 E:849 ||| VBZ
been  ||| S:849 E:854 ||| VBN
shown  ||| S:854 E:860 ||| VBN
to  ||| S:860 E:863 ||| TO
be  ||| S:863 E:866 ||| VB
very  ||| S:866 E:871 ||| RB
effective ||| S:871 E:880 ||| JJ
,  ||| S:880 E:882 ||| ,
although  ||| S:882 E:891 ||| IN
it  ||| S:891 E:894 ||| PRP
cannot  ||| S:894 E:901 ||| RB
cross  ||| S:901 E:907 ||| VB
the  ||| S:907 E:911 ||| DT
blood-brain  ||| S:911 E:923 ||| JJ
barrier ||| S:923 E:930 ||| NN
.  ||| S:930 E:932 ||| .
If  ||| S:932 E:935 ||| IN
patients  ||| S:935 E:944 ||| NNS
with  ||| S:944 E:949 ||| IN
breast  ||| S:949 E:956 ||| JJ
cancer  ||| S:956 E:963 ||| NN
who  ||| S:963 E:967 ||| WP
are  ||| S:967 E:971 ||| VBP
being  ||| S:971 E:977 ||| VBG
treated  ||| S:977 E:985 ||| VBN
with  ||| S:985 E:990 ||| IN
trastuzumab  ||| S:990 E:1002 ||| NN
and  ||| S:1002 E:1006 ||| CC
are  ||| S:1006 E:1010 ||| VBP
responding  ||| S:1010 E:1021 ||| VBG
systemically ||| S:1021 E:1033 ||| NN
,  ||| S:1033 E:1035 ||| ,
develop  ||| S:1035 E:1043 ||| VB
brain  ||| S:1043 E:1049 ||| NN
metastases ||| S:1049 E:1059 ||| NN
,  ||| S:1059 E:1061 ||| ,
then  ||| S:1061 E:1066 ||| RB
patient  ||| S:1066 E:1074 ||| JJ
prognosis  ||| S:1074 E:1084 ||| NN
does  ||| S:1084 E:1089 ||| VBZ
need  ||| S:1089 E:1094 ||| NN
to  ||| S:1094 E:1097 ||| TO
be  ||| S:1097 E:1100 ||| VB
taken  ||| S:1100 E:1106 ||| VBN
into  ||| S:1106 E:1111 ||| IN
account ||| S:1111 E:1118 ||| NN
;  ||| S:1118 E:1120 ||| :
however ||| S:1120 E:1127 ||| RB
,  ||| S:1127 E:1129 ||| ,
maintaining  ||| S:1129 E:1141 ||| VBG
treatment  ||| S:1141 E:1151 ||| NN
with  ||| S:1151 E:1156 ||| IN
trastuzumab  ||| S:1156 E:1168 ||| NN
while  ||| S:1168 E:1174 ||| IN
using  ||| S:1174 E:1180 ||| VBG
available  ||| S:1180 E:1190 ||| JJ
therapies  ||| S:1190 E:1200 ||| NNS
to  ||| S:1200 E:1203 ||| TO
treat  ||| S:1203 E:1209 ||| VB
intracranial  ||| S:1209 E:1222 ||| JJ
lesions  ||| S:1222 E:1230 ||| NNS
should  ||| S:1230 E:1237 ||| MD
be  ||| S:1237 E:1240 ||| VB
considered  ||| S:1240 E:1251 ||| VBN
as  ||| S:1251 E:1254 ||| IN
an  ||| S:1254 E:1257 ||| DT
option ||| S:1257 E:1263 ||| NN
.  ||| S:1263 E:1265 ||| .
